Floatz logo

FLUOROURACILUM

Mucinous Adenocarcinoma of the Rectum

University of Southern CaliforniaSmall moleculePhase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mucinous Adenocarcinoma of the Rectum cohort.

Asset / SponsorPhaseRating
Eloxatin
Virginia Commonwealth University
Phase 3BBB
Irinotecan
Fox Chase Cancer Center
Phase 3BBB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Aflibercept
John Hays
Phase 2B
PANITUMUMAB
John Hays
Phase 2B

View all 20 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →